Researchers looked at a class of medications called host-targeting antivirals (HTAs). Unlike some drugs that target the virus directly, these work by interfering with the host cell factors or pathways that the virus needs to replicate. This includes steps like invasion, attachment, biosynthesis, assembly, and release.
The review focused on how these treatments might compare to direct-acting antiviral drugs for conditions like the common cold, asthma, and chronic obstructive pulmonary disease. The findings suggest that HTAs could become a significant treatment strategy, especially for people at high risk of complications from rhinovirus infections.
Because this is a systematic review, it is important to note that many details are still unknown. There is currently no data on the safety or tolerability of these specific drugs in humans. Additionally, challenges remain regarding how well these drugs can be delivered and how they might work differently in different people. These findings show potential for future treatments rather than immediate changes to current care.
